Repositioning Candidate Details
| Candidate ID: | R0362 |
| Source ID: | DB01000 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Cyclacillin |
| Synonyms: | (1-aminocyclohexyl)penicillin; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(1-aminocyclohexanecarboxamido)penicillanic acid; 6-(1-aminocyclohexylcarboxamido)penicillanic acid; Ciclacillin; Cyclacillin |
| Molecular Formula: | C15H23N3O4S |
| SMILES: | [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O |
| Structure: |
|
| DrugBank Description: | A cyclohexylamido analog of penicillanic acid. |
| CAS Number: | 3485-14-1 |
| Molecular Weight: | 341.426 |
| DrugBank Indication: | For the treatment of bacterial infections caused by susceptible organisms. |
| DrugBank Pharmacology: | Cyclacillin, a penicillin, is a cyclohexylamido analog of penicillanic acid. Cyclacillin is more resistant to beta-lactamase hydrolysis than ampicillin, is much better absorbed when given by mouth and, as a result, the levels reached in the blood and in the urine are considerably higher than those obtained with the same dose of ampicillin. Cyclacillin has been replaced by newer penicillin treatments. |
| DrugBank MoA: | The bactericidal activity of cyclacillin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cyclacillin is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases. |
| Targets: | Penicillin-binding protein 1A inhibitor; Penicillin-binding protein 3 inhibitor; Penicillin binding protein 2a inhibitor; Penicillin-binding protein inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|